Trexquant Investment LP Sells 22,576 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Trexquant Investment LP trimmed its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 15.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 120,065 shares of the company’s stock after selling 22,576 shares during the quarter. Trexquant Investment LP’s holdings in Viridian Therapeutics were worth $2,302,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Loomis Sayles & Co. L P bought a new position in shares of Viridian Therapeutics during the fourth quarter worth approximately $26,845,000. Victory Capital Management Inc. acquired a new stake in Viridian Therapeutics during the fourth quarter worth approximately $7,868,000. Lord Abbett & CO. LLC bought a new position in Viridian Therapeutics during the 3rd quarter worth $8,917,000. Raymond James Financial Inc. acquired a new position in Viridian Therapeutics in the 4th quarter valued at $6,015,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Viridian Therapeutics by 218.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after acquiring an additional 274,641 shares during the period.

Analysts Set New Price Targets

A number of research firms recently commented on VRDN. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $27.00 price target (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Needham & Company LLC reiterated a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Monday, December 16th. Finally, Royal Bank of Canada upped their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $11.78 on Tuesday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a market cap of $959.89 million, a PE ratio of -2.73 and a beta of 0.81. Viridian Therapeutics, Inc. has a 12-month low of $10.88 and a 12-month high of $27.20. The business has a 50-day simple moving average of $16.04 and a two-hundred day simple moving average of $19.33.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.